Email this article Optimization of regimes of mobilization of blood hemopoietic stem cells in patients with multiple myeloma
- Authors: Pokrovskaya O.S.1, Mendeleeva L.P.1, Urnova E.S.1, Gaponova T.V.1, Gribanova E.O.1, Alekseeva I.V.1, Drokov M.Y.1, Kalinin N.N.1, Gretsov E.M.1, Klyasova G.A.1, Savchenko V.G.1, Pokrovskaya OS2, Mendeleeva LP2, Urnova ES2, Gaponova TV2, Gribanova EO2, Alekseeva IV2, Drokov MY.2, Kalinin NN2, Gretsov EM2, Klyasova GA2, Savchenko VG2
-
Affiliations:
- Hematological Research Center, Moscow
- Issue: Vol 83, No 7 (2011)
- Pages: 50-57
- Section: Editorial
- Submitted: 10.04.2020
- Published: 15.07.2011
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30886
- ID: 30886
Cite item
Full Text
Abstract
Material and methods. Department of hemoblastoses chemotherapy and bone marrow transplantation of the Russian Hematological Center performed mobilization of autologous blood hemopoietic stem cells (BHSC) in 93 MM patients treated in 2001-2010. This was done with cyclophosphamide and G-CSF. The former was used in 59 cases in a dose 6 g/m2, in 34 cases - 4 g/m2.
Results. Myelotoxic agranulocytosis after cyclophosphamide administration developed in all the patients and was observed for 3-10 days (median 5 days). Agranulocytosis ran without documented infections in 51 (54.8%) patients, with febril fever - in 42 (45.2%) patients. Cepticemia, pneumonia, necrotic enteropathy, stomatitis, herpetic lesion of the skin were registered in 9, 4, 11, 14 and 6 cases, respectively. Severe thrombocytopenia (< 30x109/l) occurred more frequently in administration of 6 g/ m2 cyclophosphamide. It was corrected with 2-5 transfusions of thromboconcentrates, only 1 transfusion was needed after the dose 4 g/m2.
Collection of CD34+ cells started in leukocyte level over 3.5x109/l on mobilization day 12-20 (median day 15). The day of the first leukocytapheresis did not depend on the day of the first introduction of G-CSF. Duration of G-CSF administration was significantly shorter in the start of its use after leukocyte count decrease under 1.0x109/l. Conduction of 1 to 5 (median 2) leukocytapheresis was needed for collection of BHSC. Sufficient for 2 autotransplantations number of BHSC were stored in 90 of 93 patients. Cyclophosphamide administration in a dose 6 g/m2 allowed collection of cells sufficient for one autotransplantation for the first leukapheresis in 52 (88.1) patients. A total number of CD34+ cells over 4x106 cells/kg were collected in 56 (94.9%) patients. In administration of cyclophosphamide in a dose 4 g/m2 mobilization was effective in all 34 patients. The first leukapheresis provided sufficient for one autotransplantation number of cells in 29 (85.3%) patients.
Conclusion. Administration of high cyclophosphamide doses in combination with G-CSF is an effective and safe method of BHSC mobilization providing collection of adequate number of CD34+ cells for double autotransplantation in 96.8% patients. Cost effective is the start of G-CSF administration in the fall of leukocytes under 1.0x109/l. Cyclophosphamide dose 4 g/m2 provides collection of CD34+ cells number sufficient for two autotransplantations in moderate thrombocytopenia and in less number of substitute transfusions in the absence of serious toxic complications.
About the authors
Ol'ga Stanislavovna Pokrovskaya
Email: sillywilly@yandex.ru
Larisa Pavlovna Mendeleeva
Email: mlp@blood.ru
Evdokiya Sergeevna Urnova
Email: eurnova@mail.ru
Tat'yana Vladimirovna Gaponova
Email: gaponova.tatj@yandex.ru
Elena Olegovna Gribanova
Email: gribanova@blood.ru
Inna Vladimirovna Alekseeva
Email: inna_alekseeva@blood.ru
Mikhail Yur'evich Drokov
Email: mdrokov@gmail.com
Nikolay Nikolaevich Kalinin
Email: kalininn@blood.ru
Evgeniy Mikhaylovich Gretsov
Galina Aleksandrovna Klyasova
Email: klias@blood.ru
Valeriy Grigor'evich Savchenko
Email: svg@blood.ru
O S Pokrovskaya
Hematological Research Center, MoscowHematological Research Center, Moscow
L P Mendeleeva
Hematological Research Center, MoscowHematological Research Center, Moscow
E S Urnova
Hematological Research Center, MoscowHematological Research Center, Moscow
T V Gaponova
Hematological Research Center, MoscowHematological Research Center, Moscow
E O Gribanova
Hematological Research Center, MoscowHematological Research Center, Moscow
I V Alekseeva
Hematological Research Center, MoscowHematological Research Center, Moscow
M Yu Drokov
Hematological Research Center, MoscowHematological Research Center, Moscow
N N Kalinin
Hematological Research Center, MoscowHematological Research Center, Moscow
E M Gretsov
Hematological Research Center, MoscowHematological Research Center, Moscow
G A Klyasova
Hematological Research Center, MoscowHematological Research Center, Moscow
V G Savchenko
Hematological Research Center, MoscowHematological Research Center, Moscow
References
- Alexanian R., Weber D., Giralt S. et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant. 2001; 27(10): 1037- 1043.
- Lahuerta J. J., Mateos M. V., Martinez-Löpez J. et al. Influence of pre- and posttransplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J. Clin. Oncol. 2008; 26(35): 5775-5782.
- Van de Velde H. J. K., Liu X., Chen G. et al. Complete response correlates with long-term survival and progresiön-free survival in high-dose therapy in multiple myeloma. Haematologica 2007; 92(10): 1399-1406.
- Harousseau J. L., Attal M., Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009 ; 114: 3139- 3146.
- Ludwig H., Beksac M., Blade J. et al. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 2010; 15: 6-25.
- Alvares C. L., Davies F. E., Horton C. et al. The role of second autografts in the management of myeloma at first relapse. Haematologica 2006; 91: 141-142.
- Olin R. L., Vogl D. T., Porter D. L. et al. Second auto-SCT is safe and effective salvage therapy for relapsed myltiple myeloma. Bone Marrow Transplant. 2009; 43(5): 417-422.
- The Joint Accreditation Committee of ISСТ-ЕURОРЕ and EBMT. Standards for hematopoietic progenitor cell collection, processing and transplantation. 2-nd ed. Istanbul; 2003.
- Bensinger W., Appelbaum F., Rowley S. et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J. Clin. oncol. 1995; 13: 2547-2555.
- Desikan K. R., Tricot G., Munshi N. C. et al. Preceding chemotherapy, tumor load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br. J. Haematol. 2001; 112(1): 242-247.
- Kumar S., Giralt S., Stadtmauer E. et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide, lenalidomide or bortezomib- containing regimens. Blood 2009; 114(9): 1729-1735.
- Rubia J., Blade J., Lahuerta J.-J. et al. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) study. Haematologica 2006; 91(5) 621-627.
- Hiwase D. K., Bollard G., Hiwase S. et al. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Cytotherapy 2007; 9(6): 539-547.
- Goldschmidt H., Hegenbart U., Haas R. et al. Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colonystimulating factor in patients with multiple myeloma. Bone Marrow Transplant. 1996; 17(5): 691-697.
- Kotasek D., Shepherd K. M., Sage R. E. et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilisation in lymphoma, myeloma, and solid tumors. Bone Marrow Transplant 1992; 9: 11-17.
- Fitoussi О., Perreau V., Boiron J. M. et al. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant. 2001; 27(8): 837-842.
- International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol. 2003; 121(5): 749-757.
- Durie B. G. M., Harousseau J.-L., Miguel J. S. et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20(9): 1467-1473.
- Goldschmidt H., Hegenbart U., Wallmeier M. et al. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br. J. Haematol. 1997; 98: 736-744.
- Prince H. M., Imrie K., Sutherland D. R. et al. Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collections. Br. J. Haematol. 1996; 93(1): 142-145.
- Менделеева Л. П., Савченко В. Г., Павлова О. А. и др. Мобилизация гранулоцитарным колониестимулирующим фактором аутологичных гемопоэтических клеток крови у больных лимфомами и раком молочной железы. Пробл. гематол. 1999; 4: 5-12.
- Зубаровская Л. С., Семенова Е. В., Бабенко Е. В. и др. Эффективность мобилизации периферических стволовых клеток крови с помощью препарата лейкостим у больных злокачественными новообразованиями. Онкогематология 2008; 1: 70-75.
- Bensinger W., DiPersio J. F., McCarty J. M. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant. 2009; 43: 181-195.
- Менделеева Л. П., Покровская О. С., Урнова Е. С. и др. Мобилизация препаратом филграстима - граногеном аутологичных гемопоэтических стволовых клеток у больных с онкогематологическими заболеваниями. Гематол. и трансфузиол. 2009; 3: 31-36.
- Менделеева Л. П., Митиш Н. Е., Клясова Г. А. и др. Инфекционные осложнения после трансплантации аутологичных гемопоэтических клеток при гемобластозах. Тер. apx. 2005; 7: 33-39.
- Кос O. N., Gerson S. L., Cooper B. W. et al. Randomized cross-over trail of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J. Clin. Oncol. 2000; 18(9): 1824-1830.
- Jantunen E., Putkonen M., Nousiainen T. et al. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilization in patients with multiple myeloma. Bone Marrow Transplant. 2003; 31: 347-351.
Supplementary files
